Key Takeaways:
- Biomerica, Inc. BMRA reported a decline in first-quarter revenue, indicating a shift in financial performance.
- The company operates in the healthcare sector, focusing on medical diagnostic products for chronic diseases.
- Financial metrics reveal challenges in profitability and growth, with significant declines in revenue and margins.
Biomerica, Inc. (BMRA) disclosed a decline in its first-quarter revenue, reporting $1.4 million compared to $1.8 million during the same period last year. This decrease highlights changes in the company’s financial performance year-over-year.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focuses on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from Asia, with additional presence in Europe, North America, the Middle East, and South America.
Biomerica operates within the healthcare sector, specifically in the medical devices and instruments industry. The company has a market capitalization of approximately $8.18 million. Despite its niche focus, Biomerica faces significant challenges in maintaining its financial health and market position.
Financial Health Analysis
Biomerica's financial metrics reveal a challenging landscape:
- Revenue Growth (3-Year): -42.1%
- Operating Margin: -96.69%
- Net Margin: -93.64%
- Gross Margin: 9.43%
- Earnings Per Share (EPS): -2.32
The company's balance sheet shows a current ratio of 2.8, indicating a reasonable level of liquidity. However, the debt-to-equity ratio stands at 0.11, suggesting limited leverage but also potential constraints on growth capital.
Warning signs include an Altman Z-Score of -11.1, placing the company in the distress zone, which implies a possibility of bankruptcy within the next two years. Additionally, the Piotroski F-Score of 3 indicates poor business operations.
Valuation & Market Sentiment
Biomerica's valuation metrics reflect its current market challenges:
- Price-to-Sales (P/S) Ratio: 1.18
- Price-to-Book (P/B) Ratio: 1.77
Technical indicators such as the Relative Strength Index (RSI-14) at 46.26 suggest that the stock is neither overbought nor oversold. The 20-day Simple Moving Average (SMA) is at 2.85, indicating a stable short-term trend.
Institutional ownership is low at 2.79%, while insider ownership is significantly high at 92.45%, which could imply confidence from insiders but also limited external validation.
Risk Assessment
Biomerica's financial health grades highlight several risks:
- The Beneish M-Score of -3.38 suggests the company is unlikely to be a manipulator.
- Sector-specific risks include regulatory changes and competitive pressures in the healthcare industry.
- The stock's beta of 0.94 indicates moderate volatility compared to the market.
Overall, Biomerica faces significant challenges in improving its financial performance and market position. Investors should consider these factors when evaluating the company's potential for recovery and growth.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
